Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 18 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Petanidis, Savvas [Clear All Filters]
(2020).
(2020).
Dual photothermal MDSCs-targeted immunotherapy inhibits lung immunosuppressive metastasis by enhancing T-cell recruitment..
Nanoscale. 12(13), 7051-7062.
(2020). Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy..
Front Oncol. 12, 1042125.
(2022). Epigenetic editing and tumor-dependent immunosuppressive signaling in head and neck malignancies..
Oncol Lett. 23(6), 196.
(2022).
(2020). Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy..
Pharmaceutics. 16(4),
(2024). Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery..
Pharmaceutics. 15(10),
(2023).
(2021).
MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells..
Cell Signal. 27(8), 1576-88.
(2015). Molecular and Immune Phenotypic Modifications during Metastatic Dissemination in Lung Carcinogenesis..
Cancers (Basel). 14(15),
(2022). Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?.
J Cancer. 11(6), 1606-1613.
(2020). Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer..
J Cancer. 8(18), 3648-3656.
(2017).
(2019).
Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer..
J Cancer. 11(11), 3407-3415.
(2020). Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis..
Clin Immunol. 222, 108620.
(2021). Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization..
Front Immunol. 14, 1325360.
(2023).
(2022).